Estimativa de custo da asma em tratamento ambulatorial: estudo com dados de mundo real

Costa, Eduardo; Caetano, Rosângela; Werneck, Guilherme Loureiro; Bregman, Mauricio; Araújo, Denizar Vianna; Rufino, Rogério

doi:10.11606/s1518-8787.2018052000153

Cited by 18 publications

(26 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Asthma is one of the most common non-communicable respiratory disease, affecting about 6% of general population, that is currently more than 300 millions of people in the world1, 2; the trend of asthma prevalence seems to be at least stable, 1 if not even increasing in the last few years 2, 3. This epidemiological situation accounts for high and increasing health-related costs (direct and indirect),4, 5, 6, 7, 8, 9 particularly in those patients with suboptimal control of asthma 10, 11…”

Section: Introductionmentioning

confidence: 99%

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

Canonica

Colombo

Bruno³

et al. 2019

World Allergy Organization Journal

View full text Add to dashboard Cite

Background Asthma is one of the most common non-communicable respiratory diseases, affecting about 6% of the general population. Severe asthma, even if afflicts a minority of asthmatics, drives the majority of costs of the disease. The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related adverse events in severe asthmatics and applying it to the first published epidemiologic data from the Severe Asthma Network in Italy (SANI) registry. Methods The analysis was conducted from the perspective of the Italian National Healthcare System (INHS). Model inputs, derived from literature, included: asthma epidemiology data, frequency of adverse events, percentage of severe asthma treated with OCS and adverse event cost (Diagnosis-Related Group (DRG) national tariffs). We estimated costs per different patient groups: non-asthma controls, mild/moderate and severe asthmatics. Final results report estimated direct cost per patient and total direct cost for overall target population, showing economic impact related to corticosteroid complication. Results Based on epidemiological data input, in Italy, asthmatic subjects resulted about 3,999,600, of which 199,980 with severe asthma. The number of patients with severe asthma OCS-treated was estimated at 123,988. Compared to the non-asthma control cohort and to that with moderate asthma annual cost per severe asthmatic patient resulted respectively about €892 and €606 higher, showing a corticosteroids shadow cost ranging from 45% to 30%. Applying the cost per patient to the target population identified for Italy, the budget impact model estimated a total annual cost related to OCS-related adverse events of €242.7 million for severe asthmatics. In respect with non-asthmatic and moderate population, an incremental expenditure of about € 110.6 million and €75.2, respectively, were shown. Conclusions Our study provides the first estimates of additional healthcare costs related to corticosteroid induced adverse events in severe asthma patient. Budget impact model results highlighted the relevant economic impact of OCS-related adverse events in severe asthma patients. The future extrapolation of additional data from SANI registry will support the development of a model to investigate the role of corticosteroids sparing drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

Canonica

Colombo

Bruno³

et al. 2019

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

“… 19 , 20 Another study found that a patient with severe asthmatic has an annual cost of US$1400, that is two to four times more when compared with patients with milder asthma. 21 …”

Section: Methodsmentioning

confidence: 99%

An expert review on breaking barriers in severe asthma in Brazil: Time to act

et al. 2021

View full text Add to dashboard Cite

Currently, Brazil lacks a national asthma management program and is burdened with nearly 200,000 hospitalizations due to the disease per year and approximately 5 deaths per day. The purpose of this article was to analyze the current issues surrounding severe asthma in Brazil, as the status of diagnosis and treatment is largely unknown, and to provide feasible recommendations to elicit imminent action. A panel of Brazilian medical experts in the field of severe asthma was provided with a series of relevant questions to address prior to a multi-day conference. Within this conference, each narrative was discussed and edited by the entire group. Through numerous rounds of discussion consensus was achieved. In order to overcome barriers to adequate asthma treatment, this panel recommends specific initiatives that can be implemented in the short-term to decrease the burden of severe asthma in Brazil. With increasing healthcare costs and limited resources globally, there is an opportunity to implement these recommendations in other countries in order to achieve adequate asthma care. Severe asthma is a heterogeneous and complex disease with various phenotypes that requires strict attention for diagnosis and management. Although this disease affects only a small proportion of the population with asthma, it poses a great burden to healthcare systems. Thus, barriers to diagnosis, treatment, and management should be overcome as quickly and efficiently as possible.

show abstract

“…(15) Uncontrolled asthma generates high costs for the health care system as well as for families. (16) In cases of severe asthma, it is estimated that this corresponds to more than a quarter of the family income among users of the Brazilian Sistema Único de Saúde (SUS, Unified Health Care System), (16,17) although the cost could be reduced significantly with the adequate control of the disease. (18) However, a nationwide survey found that only 12.3% of asthma patients had well-controlled asthma.…”

Section: Epidemiology Of Asthma In Brazilmentioning

confidence: 99%

2020 Brazilian Thoracic Association recommendations for the management of asthma

et al. 2020

View full text Add to dashboard Cite

The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the disease, as well as to minimize the risks (of exacerbations, disease instability, accelerated loss of lung function, and adverse treatment effects). That requires an approach that is personalized in terms of the pharmacological treatment, patient education, written action plan, training in correct inhaler use, and review of the inhaler technique at each office visit. A panel of 22 pulmonologists was invited to perform a critical review of recent evidence of pharmacological treatment of asthma and to prepare this set of recommendations, a treatment guide tailored to use in Brazil. The topics or questions related to the most significant changes in concepts, and consequently in the management of asthma in clinical practice, were chosen by a panel of experts. To formulate these recommendations, we asked each expert to perform a critical review of a topic or to respond to a question, on the basis of evidence in the literature. In a second phase, three experts discussed and structured all texts submitted by the others. That was followed by a third phase, in which all of the experts reviewed and discussed each recommendation. These recommendations, which are intended for physicians involved in the treatment of asthma, apply to asthma patients of all ages.

show abstract

Estimativa de custo da asma em tratamento ambulatorial: estudo com dados de mundo real

Cited by 18 publications

References 29 publications

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

An expert review on breaking barriers in severe asthma in Brazil: Time to act

2020 Brazilian Thoracic Association recommendations for the management of asthma

Contact Info

Product

Resources

About